Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This will be a study conducted as a placebo-controlled, double blind, 1:1 randomized
controlled clinical trial testing a Tumor Necrosis Factor Blocker (Anti-TNFα) substance
versus placebo in subjects with a 2-year 50% risk of progression to stage 3 T1D across
multiple centers. The trial will investigate the ability of Anti-TNFα to prevent or delay
progression to Stage 3 T1D in the targeted patient population.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)